Village Farms: Raymond James Raises Price Target To US$27

On August 16, Village Farms (NASDAQ: VFF) (TSX: VFF) announced their entrance into the US market with an acquisition of Balanced Health Botanicals, a CBD company for $75 million. Consideration is to consist of $30 million in cash and 4.7 million in shares, the equivalent of $45 million.

Balance Health Botanicals is a top-five leading CBD brand, which has done more than $30 million in annual sales with an adjusted EBITDA margin of 15%.

Village Farms currently has 6 analysts covering the stock with an average 12-month price target of $23.71, or a 103% upside. Out of the 6 analysts, 1 has a strong buy rating and the other 5 have buy ratings. The street high sits at $33.79 from Raymond James, while the lowest comes in at $17.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Raymond James was the only analyst to raise their 12-month price target from U$26 to U$27 and reiterated their strong buy rating on the name, saying that Village can use their “big box” network to provide synergies.

Raymond James says that this acquisition shows “another successful step in VFF’s evolution into a proper CPG company, and having the potential to yield plenty of synergy with VFF’s existing operations.”

They give two large benefits and synergies with the deal, the first being that Village Farm’s fresh produce business is adjacent to Balanced Health’s products, with Village being a producer for over 30 years. They have the ability to “supercharge” Balanced Health’s product sales.

The second being the most obvious, it helps Village to build a network that could be flipped into selling THC products once legal. They say, “Today’s acquisition provides yet another direct route into the U.S. cannabis market,” and “We believe this acquisition secures an important part of VFF’s supply chain, priming its nationwide networks for when the company begins cultivating, manufacturing, packaging, and selling both CBD and high-THC cannabis products in the U.S.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Copper Mine Costs 1/6 to Restart | SSR Mining X Roxmore

Why Cambria Hit Pause on Its Massive Copper-Gold Spinout

Can Gold Rescue Washington From Its Debt Trap? | Andy Schectman – Miles Franklin

Recommended

Blue Jay Gold Signs Ocean Partners Deal to Ship Steller Stockpiles Through 2027

Krait Critical Minerals Signs Option for Historical Nevada King Antimony Mine

Related News

Canaccord: IAMGOLD Has “Few Desirable Options To Plug Funding Gap”

On May 3, IAMGOLD Corporation (TSX: IMG) reported its first quarter results for 2022. The...

Thursday, May 5, 2022, 02:24:00 PM

Curaleaf: Haywood Reiterates $22 Price Target, Names Firm A Top Pick For 2022

On December 28th, Curaleaf Holdings (CSE: CURA) announced that they have entered into a definitive agreement...

Friday, December 31, 2021, 04:35:00 PM

Cresco Labs: Stifel Slashes Price Target From $30 To $8 Following Poor Q4 Results

On March 23rd, Cresco Labs (CSE: CL) announced its fourth-quarter financial results, which disappointed many...

Friday, March 25, 2022, 03:39:00 PM

US Cannabis: Stifel Expects “Limited To No Sales Growth”

Earlier this month, Stifel-GMP came out with their US cannabis second quarter preview, calling the...

Monday, August 1, 2022, 01:17:00 PM

Canaccord Drops Antibe’s Price Target To $0.70 Following Asset Sale

Antibe Therapeutics Inc. (TSX: ATE) recently reported their full-year 2022 results, wherein the company reported...

Friday, July 15, 2022, 02:25:00 PM